Although several studies have proven that cannabis can treat conditions such as chronic pain, medical cannabis patients do not have a safe way to consume the plant. Save for taking the cannabis orally, most means of consumption such as smoking the flower and vaping come with a degree of risk. And since a large portion of medical cannabis patients are either older or they have compromised immune systems, any risk could be fatal.
Syqe Medical, a pharma-tech company based in Israel, has developed a proprietary medical cannabis delivery device that offers medical marijuana patients a much safer, more precise means of taking their medicine. The device, which has been dubbed the Syqe Inhaler, has been approved by Canadian Health officials and will soon be available to qualified Canadian patients. The Israeli company will sell the medical cannabis delivery device in partnership with a Canadian licensed producer via Syqe Medical Canada.
The technology behind the portable, handheld delivery device has been through a decade of extensive research and development, says Syqe Medical Canada’s General Manager Michael Molloy. This includes testing in a variety of research trials, and it resulted in the creation of a delivery device capable of releasing a controlled amount of cannabinoids in each inhalation. Not only will patients have a much safer way to take their medicine, but they will also be able to take precisely measured doses, a feat that has been pretty unachievable so far.
According to the medical director at Canada’s Centers for Pain Management, “unreliable dosing methods” such as smoking have hampered medical cannabis use. Consequently, physicians and patients alike have been looking for an alternative that would allow precise dosing each time, and the Syqe Inhaler fits this description perfectly. After raising more than $80 million in funding and spending close to a decade on research and development, the Tel Aviv-based firm came up with a metered-dose inhaler that met regulatory standards and is now eligible for distribution, at least in Canada.
Data from clinical trials done at Rambam Health Center located in Haifa, Israel, as well as data obtained from Israeli patients who had used the inhaler was instrumental in gaining Canada’s approval. The Canadian market has 370,000 registered medical cannabis patients and more than 5.8 million Canadian residents in total suffer from chronic pain. Projections put the market’s worth at around $380 million by 2024, and it will provide a major boost to Syqe’s business growth plan, the Israeli pharma-tech company said.
With lots of companies, such as Sonoma Biologics Corp., supplying high-grade medical cannabis in U.S. markets, it won’t be long before Syqe’s or other such devices are commercialized and made available to those who need them in all jurisdictions with legal medical marijuana programs.
NOTE TO INVESTORS: The latest news and updates relating to Sonoma Biologics Corp. are available in the company’s newsroom at https://cnw.fm/Sonoma
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.